Compare DAO & SUPN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DAO | SUPN |
|---|---|---|
| Founded | 2006 | 2005 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.2B | 2.5B |
| IPO Year | 2019 | 2010 |
| Metric | DAO | SUPN |
|---|---|---|
| Price | $19.19 | $40.72 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 7 | 4 |
| Target Price | $19.92 | ★ $60.50 |
| AVG Volume (30 Days) | 26.5K | ★ 776.4K |
| Earning Date | 11-19-2026 | 10-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $392,755,000.00 |
| Revenue This Year | $8.23 | $21.56 |
| Revenue Next Year | $14.68 | $55.45 |
| P/E Ratio | $72.35 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $8.38 | $37.54 |
| 52 Week High | $19.81 | $59.68 |
| Indicator | DAO | SUPN |
|---|---|---|
| Relative Strength Index (RSI) | 64.34 | 43.72 |
| Support Level | $9.60 | $37.54 |
| Resistance Level | N/A | $52.30 |
| Average True Range (ATR) | 1.04 | 1.77 |
| MACD | 0.14 | 0.03 |
| Stochastic Oscillator | 82.61 | 50.64 |
Youdao Inc develops and markets software applications. It engages in developing technologies to provide learning content, applications, and solutions. The firm operates in three segments: Learning services, Smart devices, and Online marketing services. The majority of its revenue comes from the Learning services segment, which generates revenues from online courses, mainly including Youdao Premium Courses, NetEase Cloud Classroom, and China University MOOC. The learning products segment includes sales of smart devices such as the Youdao Dictionary Pen and the Youdao Pocket Translator. Geographically, all of its revenue is generated from the People's Republic of China.
Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. Its diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The company's products include Trokendi XR, Oxtellar XR, Qelbree, APOKYN, XADAGO, MYOBLOC, GOCOVRI, Osmolex ER, and others.